ClinicalTrials.gg
CompletedNCT00476099Updated Oct 29, 2021

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

A Phase 3 interventional study of Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI and Budesonide 200 µg plus formoterol 6 µg DPI in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
828
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
7th of 43
828 · median 99
Started
2006
with 2 others
Phase 3
15 of 43
1 open now
Registered
5th of 43
by date
Lead sponsor
1 of 43
Chiesi Farmaceutici S.p.A.

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 7th largest by enrollment, is one of 3 that started in 2006, is one of 15 in phase 3, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.

Read the detailed description

The purpose of this study is to evaluate the long-term efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD. Patients are randomised to receive either beclometasone/formoterol or budesonide/formoterol DPI or formoterol DPI during 48 weeks of treatment.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of (according to GOLD guidelines)
  • > or equal 30% and \< 50% of predicted normal post-bronchodilator (and at least 0.7 L absolute value)
  • COPD symptoms for at least 2 years
  • At least 1 exacerbation requiring medical intervention (oral and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 2-12 months before screening
  • Current or previous smoker with a cumulative exposure to smoke of more than 20-pack year

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of asthma, or any evidence suggestive of asthma
  • Positive reversibility test
  • or unstable concurrent diseases, including clinically significant laboratory abnormalities
  • Acute exacerbation or lower tract infection and/or treatment with oral or injectable and antibiotics in the 2 months before screening or during run-in
  • Long term oxygen therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
828 participants (actual)

Study arms

  • Experimental
    Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI

    Drug: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI · Drug: Budesonide 200 µg plus formoterol 6 µg DPI · Drug: Formoterol 12 µg DPI

  • Active comparator
    Budesonide 200 µg plus formoterol 6 µg DPI

    Drug: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI · Drug: Budesonide 200 µg plus formoterol 6 µg DPI · Drug: Formoterol 12 µg DPI

  • Active comparator
    Formoterol 12 µg DPI

    Drug: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI · Drug: Budesonide 200 µg plus formoterol 6 µg DPI · Drug: Formoterol 12 µg DPI

Interventions

  • DrugBeclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI

    Drug page: BeclomethasoneStudies of BeclomethasoneBeclomethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

  • DrugBudesonide 200 µg plus formoterol 6 µg DPI

    Drug page: BudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.

  • DrugFormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

06

What researchers measure

Primary outcomes

  1. Number of COPD exacerbations and pre-dose morning FEV1

    Time frame: one year treatment

Secondary outcomes

  1. Other pulmonary function parameters,

    Time frame: one year treatment

  2. COPD symptom scores and Quality of Life,

    Time frame: one year treatment

  3. safety and tolerability

    Time frame: one year treatment

07

Study locations

1 site
  • Thomas Similowski
    Paris, 75000, France
08

References and documents

Publications

  • Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med. 2016 Jun 16;26:16030. doi: 10.1038/npjpcrm.2016.30. PubMed 27309985 ↗
  • Calverley PM, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010 Dec;104(12):1858-68. doi: 10.1016/j.rmed.2010.09.008. Epub 2010 Oct 20. PubMed 20965712 ↗

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Aug 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2007
First posted
May 21, 2007
Start
Dec 2006
Primary completionActual
Aug 2008
CompletionActual
Nov 2008
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00476099
Responsible party
Sponsor
First posted
May 21, 2007
Start date
Dec 2006
Primary completion
Aug 2008
Completion
Nov 2008
Last update
Oct 29, 2021

Study contacts

Peter M.A. Calverley, Professor
principal investigator · Department of Medicine, Clinical Sciences Center University Hospital Aintree, Liverpool, United Kingdom

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion